Intellia Therapeutics Inc. share price logo

Intellia Therapeutics Inc. Share Price

NASDAQ: NTLA

Mid Cap

$11.56

+0.14

(+1.23%)

as on

Intellia Therapeutics Inc. Stock Performance

as on September 16, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $11.38
    $12.04
    downward going graph

    1.56%

    Downside

    4.15%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.9
    $23.76
    downward going graph

    48.96%

    Downside

    105.54%

    Upside

    downward going graph

Intellia Therapeutics Inc. share price movements today

Previous Close
$11.42
Open
$11.80
Volume
3.3M
Day's Low - High
$11.38 - $12.04
52 Week Low - High
$5.9 - $23.76

Intellia Therapeutics Inc. Historical Returns

1 Month Return
+ 3.91 %
3 Month Return
+ 37.42 %
1 Year Return
-48.26 %
3 Year Return
-83.35 %
5 Year Return
-48.72 %

Intellia Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Intellia Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.2B

EPS (TTM)

-4.07

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.59

Industry PE ratio

10.127857142857144

P/B Ratio

0

PEG Ratio

-0.0969

EBITDA

-501.9M

Revenue (TTM)

52.9M

Profit Margin

0.00%

Return On Equity TTM

55230400.00%

Intellia Therapeutics Inc. Stock Valuation

Track how Intellia Therapeutics Inc. P/E has moved over time to understand its valuation trends.

Intellia Therapeutics Inc. in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 15, 2025

Today (-4.59x)

September 15, 2025

Industry (10.13x)

September 15, 2025

Highest (0.00x)

September 15, 2025

LowHigh

Today’s Price to Earnings Ratio: -4.59x

Intellia Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Intellia Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Intellia Therapeutics Inc. image
Intellia Therapeutics Inc.
BUY$1.2B-48.72%-4.590.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$61.1B256.98%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$38.7BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$101.1B47.85%28.0731.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$59.4B-3.43%14.1131.37%

Stock Returns calculator for Intellia Therapeutics Inc. Stock including INR - Dollar returns

The Intellia Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Intellia Therapeutics Inc. investment value today

Current value as on today

₹57,364

Returns

₹42,636

(-42.64%)

Returns from Intellia Therapeutics Inc. Stock

₹47,621 (-47.62%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on Intellia Therapeutics Inc. Stock

Based on 34 analysts

BUY

79.41%

Buy

20.59%

Hold

0.00%

Sell

Based on 34 analysts, 79.41% of analysts recommend a 'BUY' rating for Intellia Therapeutics Inc.. Average target price of $34.45

Intellia Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Intellia Therapeutics Inc..

What analysts predicted

66.44%UPSIDE

Target Price

$34.45

Current Price

$11.56

Analyzed by

34 Analysts

Target

$34.45

Intellia Therapeutics Inc. target price $34.45, a slight upside of 66.44% compared to current price of $11.56. According to 34 analysts rating.

Intellia Therapeutics Inc. Stock's Interest Amongst Investors

Investment in Intellia Therapeutics Inc. Shares on INDmoney has dropped by -59.25% over the past 30 days, indicating reduced transactional activity.

Time period: to

Change:-59.25% versus previous 30 day period

Search interest for Intellia Therapeutics Inc. Stock has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-24% versus previous 30 day period

Intellia Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
12
13
11
-1
28
6
9
12
16
14
Gross Profit
10
11
9
-4
26
4
9
7
16
14
Operating Income
-111
-132
-131
-139
-114
-139
-144
-136
-120
-109
EBITDA
-109
-130
-128
-137
-111
-136
-142
-133
-118
-107
Interest Expense
8
-
-
8
-
-
-
-
-
-
Depreciation
2
2
2
2
2
2
2
2
2
2
Income Before Tax
-103
-123
-122
-132
-107
-146
-135
-128
-114
-101
Income Tax Expense
-10
-14
-15
40
2
-
-
-
-
-
Net Income
-92
-123
-122
-132
-107
-146
-135
-128
-114
-101
Net Profit Margin
-732.54%
-909.82%
-1019.21%
6894.16%
-371.30%
-2112.62%
-1489.54%
-1001.23%
-687.61%
-710.81%

Intellia Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
6
16
26
30
43
57
33
52
36
57
Gross Profit
-5
16
26
30
-65
57
33
44
27
47
Operating Income
-13
-32
-69
-90
-106
-136
-267
-458
-515
-534
EBITDA
-13
-31
-66
-86
-100
-130
-260
-450
-506
-523
Interest Expense
-
-
-
-
-
2
6
8
-
-
Depreciation
-
-
2
4
5
6
6
7
8
10
Income Before Tax
-13
-31
-67
-85
-99
-134
-267
-474
-481
-519
Income Tax Expense
-1
-1
-2
5
-6
-8
-8
16
-49
-
Net Income
-12
-31
-67
-85
-99
-125
-259
-474
-481
-519
Net Profit Margin
-205.11%
-191.97%
-258.62%
-280.42%
-230.92%
-216.52%
-785.76%
-909.78%
-1326.51%
-896.77%

Intellia Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-123
-122
-132
-107
-146
-135
-128
-114
-101
Operating Cash Flow
-90
-101
-93
-120
-58
-84
-85
-148
-99
Investing Cash Flow
-34
79
45
5
-24
-7
151
94
106
Financing Cash Flow
2
19
106
59
41
82
2
-
14
Change in Cash
-122
-2
59
-54
-41
-10
68
-54
21

Intellia Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-31
-67
-85
-99
-134
-267
-474
-481
-519
Operating Cash Flow
36
-65
-61
-103
-49
-225
-333
-394
-348
Investing Cash Flow
-6
-10
-260
25
-214
-550
160
-31
125
Financing Cash Flow
167
142
40
76
371
736
582
130
185
Change in Cash
197
67
-281
-1
107
-39
409
-295
-37

Global Institutional Holdings in Intellia Therapeutics Inc.

Funds
Holdings
ARK Investment Management LLC
12.13%
Vanguard Group Inc
10.02%
BlackRock Inc
9.83%
State Street Corp
4.2%
Morgan Stanley - Brokerage Accounts
3.54%
See all

Insights on Intellia Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 5 quarters, -146.97M → -101.25M (in $), with an average increase of 9.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 123.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 123.5% return, outperforming this stock by 206.8%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 16.62M → 14.24M (in $), with an average decrease of 14.3% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, NTLA stock has moved down by -3.5%

About Intellia Therapeutics Inc.

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
OrganisationIntellia Therapeutics Inc.
Headquarters40 Erie Street, Cambridge, MA, United States, 02139
IndustryHealth Technology
CEODr. John M. Leonard M.D.
E-voting on sharesClick here to vote

Key Management of Intellia Therapeutics Inc.

Name

Title

Mr. Edward J. Dulac III

Executive Vice President, Chief Financial Officer and Treasurer

Mr. James E. Basta Esq., J.D.

Executive VP, General Counsel & Corporate Secretary

Dr. Jennifer A. Doudna Ph.D.

Founder & Member of Scientific Advisor Board

Dr. Rodolphe Barrangou M.B.A., Ph.D.

Founder & Member of Scientific Advisor Board

Dr. John M. Leonard M.D.

President, CEO & Director

Dr. Laura Sepp-Lorenzino Ph.D.

Special Advisor to the Chief Executive Officer

Dr. David Lebwohl M.D.

Executive VP & Chief Medical Officer

Dr. Rachel E. Haurwitz Ph.D.

Co-Founder

Dr. Derrick J. Rossi Ph.D.

Founder & Member of Scientific Advisor Board

Mr. Michael P. Dube

VP, CAO & Principal Accounting Officer

FAQs

What is Intellia Therapeutics Inc. share price today?

Intellia Therapeutics Inc. share price today is $11.56 as on at the close of the market. Intellia Therapeutics Inc. share today touched a day high of $12.04 and a low of $11.38.

What is the 52 week high and 52 week low for Intellia Therapeutics Inc. share?

Intellia Therapeutics Inc. share touched a 52 week high of $23.76 on and a 52 week low of $5.9 on . Intellia Therapeutics Inc. stock price today i.e. is closed at $11.56,which is 51.35% down from its 52 week high and 95.93% up from its 52 week low.

What is Intellia Therapeutics Inc.'s market capitalisation today?

Intellia Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Intellia Therapeutics Inc. Stock (NTLA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Intellia Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Intellia Therapeutics Inc. Shares that will get you 0.1298 shares as per Intellia Therapeutics Inc. share price of $11.56 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Intellia Therapeutics Inc. Stock (NTLA) from India?

Indian investors can start investing in Intellia Therapeutics Inc. (NTLA) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Intellia Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Intellia Therapeutics Inc. share’s latest price of $11.56 as on September 16, 2025 at 1:29 am IST, you will get 0.8651 shares of Intellia Therapeutics Inc.. Learn more about fractional shares .

What are the returns that Intellia Therapeutics Inc. has given to Indian investors in the last 5 years?

Intellia Therapeutics Inc. stock has given -48.72% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?